DEV ONLY

NantHealth Files Registration Statement for Proposed IPO

0 0

NantHealth today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

All shares of common stock to be sold in the offering will be offered by NantHealth. The number of shares to be offered and the price range for the proposed offering have not yet been determined. NantHealth intends to list its common stock on the NASDAQ Global Market under the ticker symbol “NH.”

Joining BlackBerry as investors in NantHealth are Allscripts, Verizon, Kuwait, and Celgene. The S-1 filing with the Securities and Exchange Commission on May 6, 2016 breaks down the revenues for NantHealth and highlights their plans to expand aggressively in the UK, Canada and Southeast Asia.

The fiing also lays out the plans for their knowledge, provider and payer platform known as CLINICS, short for Comprehensive Learning Integrated NantHealth Intelligent Clinical System.

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering, and First Analysis Securities Corporation and FBR Capital Markets & Co. are acting as co-managers.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from: Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by email at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806 or by fax at (631) 254-7140.
[signoff predefined=”Enjoy this?” icon=”users”][/signoff]